Matthew Walsh

Catalent Pharma Solutions, Inc. engages in the development, manufacture, and sale of pharmaceutical products. It operates through the following segments: Development and Clinical Services, Oral Technologies, and Medication Delivery Solutions. The Development and Clinical Services segment manufactures, packs, stores distributes, and manages inventory for global clinical trials of drugs and biologics. The Oral Technologies segment formulates, develops, and manufactures prescription and consumer health products using various technologies. The Medication Delivery Solutions segment develops, formulates, and manufactures prefilled syringes and other injectable formats. The company was founded in 2002 and is headquartered in Somerset, NJ.

GenTek, Inc. manufactures industrial components and performance chemicals. It offers ground and flight instrumentation, complete environmental testing, industrial and process control, satellite tracking and control, and aircraft structural testing. The company was founded in 1994 and is headquartered in Tampa, FL.

Multi-Color Corp. engages in the provision of label solutions supporting. Its products include pressure sensitive labels, in-mold labels, heat transfer labels, glue-applied labels, shrink sleeve labels, and graphic services. The company was founded in 1916 and is headquartered in Batavia, OH.

Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland.

Allergan GI Corp. develops peptide therapeutics for the treatment of gastrointestinal disorders. It provides RM-493 a small-peptide melanocortin-4 receptor agonist, for the treatment of obesity and diabetes, and RM-131 a small-peptide ghrelin agonist, for the treatment of diabetic gastro paresis and other gastrointestinal functional disorders. The company was founded by Bart Henderson and Elizabeth Stoner in 2008 and is headquartered in Madison, NJ.